Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3

What Was Tested

The paper reports a study of Bradykinin and Icatibant, published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

In the open-label extension phase, patients could receive up to three icatibant injections per attack.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label, placebo-controlled and multicenter study.

Because people in this Bradykinin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Bradykinin.

Everyone knew when Bradykinin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The comparison arm used a placebo, so changes seen with Bradykinin could be set against what happens without it.

Open-label icatibant was administered for severe laryngeal symptoms.

What Was Measured

PubMed files the paper under topics including Angioedemas, Hereditary, Bradykinin, Bradykinin B2 Receptor Antagonists and Recurrence.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Bradykinin and Icatibant.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (International archives of allergy and immunology), a journal based in Switzerland.

More context: the Bradykinin compound page and the Icatibant compound page, all human trials.